Previous 10 | Next 10 |
Silverback Therapeutics (SBTX): Q1 GAAP EPS of -$0.54 misses by $0.17.Cash and cash equivalents of $374.2MPress Release For further details see: Silverback Therapeutics EPS misses by $0.17
Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infec...
SBT6290 Shown to Activate Myeloid Cells and Drive Anti-tumor Effects in Nectin4-expressing Solid Tumors Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platf...
Silverback Therapeutics (SBTX): Q4 GAAP EPS of -$1.37 misses by $0.79.Cash and cash equivalents of $386.6M.Press Release For further details see: Silverback Therapeutics EPS misses by $0.79
Initiated SBT6050 clinical development, with pharmacological activity demonstrated in the first dose cohort Advanced preclinical development of SBT6290 and declared SBT8230 as the development candidate for chronic hepatitis B virus program Raised $441.2 million includi...
Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infec...
The following slide deck was published by Silverback Therapeutics, Inc. in conjunction with this event. For further details see: Silverback Therapeutics (SBTX) Investor Presentation - Slideshow
Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infec...
After a monumental year for biopharma investment in 2020, how much of that momentum can the sector carry over into the new year? Market watchers are beginning to place their bets. This year, the annual Biotech Showcase event went digital in the face of the global COVID-19 pandemic, ...
As the post-IPO quiet period ends for Silverback Therapeutics (SBTX), Goldman Sachs weighs in on the stock with a buy recommendation, citing the company’s unique platform targeting the immune system.The price target is $43, implying only ~14.2% upside on today’s close after the ...
News, Short Squeeze, Breakout and More Instantly...
Silverback Therapeutics Inc. Company Name:
SBTX Stock Symbol:
NASDAQ Market:
CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat dose PK/PD study of neffy under NAC conditions and updated ...
Response addresses all additional requests in FDA CRL, including positive data from a repeat dose PK/PD study of neffy under nasal allergen challenge (NAC) conditions, and updated testing that detected no measurable nitrosamine levels, conducted per August 2023 FDA Guidance Submission...
Preparing to submit response to the FDA’s CRL for neffy ® (epinephrine nasal spray) in Type I allergic reactions in early Q2 2024, following successful completion of neffy repeat dose nasal allergen challenge study and nitrosamine assessments, with ...